New-Onset Psychotic Symptoms Following Abrupt Buprenorphine/Naloxone Discontinuation in a Female Patient with Bipolar Disorder: A Case Report

Psychopharmacol Bull. 2022 Jun 27;52(3):72-80.

Abstract

Buprenorphine and naloxone (Suboxone) is a combination medication-assisted treatment (MAT) for opioid use disorder. MAT withdrawal-induced psychosis is a rare clinical presentation. To our best knowledge, only three reports have summarized the characteristic manifestations of buprenorphine withdrawal psychosis, yet all of them were male. In this case report, we present a 41-year-old female patient with bipolar disorder and comorbid substance use disorder who developed new-onset psychosis and relapse of manic symptoms following abrupt discontinuation of Suboxone. Manic and psychotic symptoms remitted after a short-term hospitalization with the treatment of an antipsychotic and a mood stabilizer. In addition to discussing this case presentation and treatment approach, we review existing literature and discuss possible underlying mechanisms to enhance understanding of this clinical phenomenon.

Keywords: buprenorphine; mania; psychosis; substance-withdrawal; two-hit hypothesis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Antipsychotic Agents* / therapeutic use
  • Bipolar Disorder* / drug therapy
  • Buprenorphine* / adverse effects
  • Buprenorphine, Naloxone Drug Combination / therapeutic use
  • Female
  • Humans
  • Male
  • Naloxone / adverse effects
  • Psychotic Disorders* / drug therapy
  • Substance Withdrawal Syndrome* / drug therapy
  • Substance Withdrawal Syndrome* / etiology

Substances

  • Antipsychotic Agents
  • Buprenorphine, Naloxone Drug Combination
  • Naloxone
  • Buprenorphine